Chinese Rheumatism Biobank(CRB)
Early prediction of major organ damage in SLE needs to dynamically track the evolution of SLE patients before and after the onset of major organ damage, and analyze the microscopic molecular evolution patterns synchronized with the macroscopic pathophysiological changes.
| Condition(s) | Lupus Erythematosus, Systemic |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Early prediction of major organ damage in SLE needs to dynamically track the evolution of SLE patients before and after the onset of major organ damage, and analyze the microscopic molecular evolution patterns synchronized with the macroscopic pathophysiological changes. |
| Who can participate | Inclusion Criteria: 1. Patients meet the 2012 SLICC classification criteria or 2019 ACR/EULAR classification criteria of SLE. 2. Disease Duration ≤2 years since SLE diagnosis at baseline 3. Non-Organ-Threatening Disease, including BILAG-2004 categories A/B/C in neurological, cardiopulmonary, gastrointestinal, ophthalmic, renal, or hematological domains Specifically excluded: Renal: Cellular casts, hematuria (\>5 RBC/hpf), proteinuria (\>0.5g/24hr), pyuria (\>5 WBC/hpf), or biopsy-proven lupus nephritis Neuropsychiatric: Seizures, psychosis, organic brain syndrome, cerebrovascular events Cardiopulmonary: Pulmonary arterial hypertension, myocarditis, pulmonary hemorrhage Vasculitis: Ulcerative/necrotizing lesions or biopsy-proven vasculitis Hematologic: Hemolytic anemia, thrombocytopenia (\< |
| Sex | All |
| Lead sponsor | Chinese SLE Treatment And Research Group |
| Locations | Beijing, Beijing Municipality, China |
| Start date | 2025-02-10 |
| NCT ID | NCT06887517 |
| Official listing | https://clinicaltrials.gov/study/NCT06887517 |